Clinical Trial Update: FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line FOLFOX/bevacizumab with onartuzumab (MetMAb) vs placebo in metastatic colorectal cancer; the update does not include results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Onartuzumab (onartuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED